Nektar Therapeutics
NKTRHealthcare|Biotechnology|USA
$70.36
-2.55 (-3.50%)
Tangible Book
$19.55
Upcoming Data Readouts (2)
Dec 2027
Est. completion
P2Lung Cancer
REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)
NCT05632809n=39
May 2028
Est. completion
P3Moderate-to-Severe Atopic Dermatitis
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07690371n=510
Awaiting Results (4)
Trials past primary completion date but still active — data readout may be imminent.
Nov 2025
P2
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
NCT06340360Sep 2025
P1
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
NCT05359211Jun 2025
P2
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
NCT05327530May 2025
P2
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT06136741